---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-032700"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2024-08-16T23:59:59+00:00"
generated_at: "2026-05-31T08:51:24.811907+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics appoints Gregory S. Curhan as CFO, replaces departing interim CFO Andrea Park

## Summary
- Gregory S. Curhan appointed CFO effective Aug 16, 2024; compensated at $650/hour plus 250k-share option vesting over 48 months.
- Andrea Park, interim CFO and CAO, departs effective Aug 15, 2024.
- Curhan is partner at FLG Partners and also CFO of Curevo Vaccines.
- Option accelerates on change of control or $60M equity transaction.

## SEC filing metadata
- accession: 0001493152-24-032700
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2024-08-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315224032700/0001493152-24-032700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315224032700/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-032700
- JSON: https://secwatch.observer/filing/0001493152-24-032700.json
- Plain text: https://secwatch.observer/filing/0001493152-24-032700.txt

## Key facts
- Executive change
  Gregory S. Curhan was appointed as Chief Financial Officer at Serina Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On August 15, 2024, the Board of Directors (the “Board”) of Serina Therapeutics, Inc. (the “Company”) appointed Gregory S. Curhan as the Company’s Chief Financial Officer in a non-employee consultant role, effective August 16, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315224032700/0001493152-24-032700-index.htm
- Executive change
  Andrea Park departed as Interim Chief Financial Officer and Chief Accounting Officer at Serina Therapeutics, Inc..
  - Action: informed that employment will end
  - Role: Interim Chief Financial Officer and Chief Accounting Officer
  source text: On August 12, 2024, the Company informed Andrea Park, the Company’s Interim Chief Financial Officer and Chief Accounting Officer, that her employment with the Company will end effective August 15, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315224032700/0001493152-24-032700-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.